US 11622970
BCL-2 inhibitors and their use as pharmaceuticals
granted A61KA61K31/635A61K45/06
Quick answer
US patent 11622970 (BCL-2 inhibitors and their use as pharmaceuticals) held by Prelude Therapeutics, Incorporated expires Mon Apr 06 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Prelude Therapeutics, Incorporated
- Grant date
- Tue Apr 11 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Apr 06 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 20
- CPC classes
- A61K, A61K31/635, A61K45/06, A61P, A61P35/00